Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.91M | -37.55M | -72.70M | -72.70M | -118.79M |
| Total Depreciation and Amortization | 156.00K | 160.00K | 221.00K | 208.00K | 315.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.13M | 5.08M | 41.51M | 14.61M | 117.83M |
| Change in Net Operating Assets | -9.20M | -26.70M | -10.60M | -8.70M | 164.00K |
| Cash from Operations | -39.82M | -59.01M | -41.57M | -66.58M | -489.00K |
| Capital Expenditure | -11.00K | -20.00K | -36.18M | -89.00K | -67.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -43.65M | 65.00M | 75.00M | -28.87M | 886.00K |
| Cash from Investing | -43.66M | 64.98M | 38.82M | -28.96M | 819.00K |
| Total Debt Issued | 65.58M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 970.00K | 148.00K | 491.00K | 47.00K | 1.45M |
| Repurchase of Common Stock | -885.00K | -38.00K | -411.00K | -20.00K | -1.32M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 65.66M | 110.00K | 80.00K | 27.00K | 131.00K |
| Foreign Exchange rate Adjustments | 197.00K | -525.00K | 236.00K | -39.00K | -110.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.62M | 5.56M | -2.44M | -95.55M | 351.00K |